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Study Objective. To determine the feasibility of using geographic information
system (GIS) technology to identify geographic areas of high and low
adherence to cardiovascular drug therapy for treatment of acute coronary
syndrome (ACS) in patients discharged from a university-affiliated hospital.
Design. Retrospective analysis.
Data Source. A registry of patients admitted to and discharged from a large
university-affiliated medical center for the treatment of ACS.
Patients. A total of 1081 adults distributed over 300 census tracts who were
discharged between April 1999 and December 2004 with a diagnosis of an
ACS event of unstable angina or acute myocardial infarction.
Measurements and Main Results. Data were collected on patient demographics,
home addresses, and adherence to four classes of drugs—statins,
angiotensin-converting enzyme inhibitors, -blockers, and aspirin—at
6–12 months after discharge for the ACS index event.  A GIS program was
used to map patient addresses and adherence data to geographic
coordinates.  Hot Spot Analysis was used to determine the existence of any
spatial clustering patterns in adherence rates.  The analysis was performed
at the census tract level by using the percentage of nonadherent patients
within a census tract to represent adherence for the people living within
that tract, standardized by the number of residents in a census tract aged 40
years or older.  Hot Spot Analysis identified unique geographic areas of
high, neutral, and low adherence in the southeast area.  Highly adherent
census tracts were primarily located in and around the city where the
university hospital and clinics are located.  Areas of low adherence were
located to the west, southwest, and southeast of the city.  All other census
tracts were considered neutral in adherence rates.
Conclusion. Mapping geographic areas of drug adherence is feasible with use
of GIS technology, with spatial mapping able to detect areas of varying
levels of adherence.  Future research should examine local-level factors
associated with low adherence, which can be used to derive tailored, locally
relevant interventions to improve long-term drug adherence.
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medication adherence, cardiovascular disease, acute coronary syndrome, ACS.
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Acute coronary syndrome (ACS) encompasses
several clinical conditions, including ST-segment
elevation myocardial infarction (STEMI),
non–ST-segment elevation myocardial infarction
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(NSTEMI), and unstable angina.  In 2004, the
American College of Cardiology and the
American Heart Association published evidence-
based guidelines for the treatment of ACS.1
Based on evidence from randomized controlled
trials, four classes of drugs are recommended for
the treatment of patients with ACS:  angio-
tension-converting enzyme (ACE) inhibitors, -
blockers, statins, and antiplatelet drugs.  Since
the publication of these guidelines, changes in
pharmacologic therapy and interventions for ACS
have significantly reduced the number of in-
hospital deaths, cardiogenic shock, recurrent
myocardial infarction, and heart failure in
patients with STEMI and NSTEMI.2
On discharge, these drugs should be continued
to prevent secondary cardiovascular events.
However, nonadherence is very common in
patients with cardiovascular disease, often leading
to increased mortality and hospitalizations.3–5
Nonadherence has been shown to significantly
increase the likelihood of death within 1 year
after a myocardial infarction.6 For example,
higher rates of death and acute myocardial infarc-
tion were observed in patients who prematurely
stopped treatment with clopidogrel.7
There are many patient-specific factors that
contribute to nonadherence, some of which
include age and race-ethnicity, polypharmacy,
frequency of drug changes, socioeconomic status,
access to medical care, out-of-pocket drug cost,
lack of prescription drug insurance, and poor
communication between patients and health care
providers.8–13 In addition, beliefs and attitudes
about illness and drugs influence adherence to
drug regimens.8, 14 Patients may alter their drug
regimens based on their perceptions of the effec-
tiveness of the drugs, the constraints of everyday
life, and any adverse effects they experience.15, 16
The focus of research on medication-taking
behavior has been on patient-level factors.
Identification of these important variables often
leads to development of patient-centered inter-
ventions tailored to the patient’s specific needs.
An approach to modifying behavior used in the
public health arena is to target populations and
their environments rather than individuals.17
Researchers are beginning to examine the envi-
ronment in which individuals live in an attempt
to identify determinants of illness, as well as the
existence of modifiable risk behaviors in popula-
tions.  Individuals of low socioeconomic position
are at greater risk of developing cardiovascular
disease, and those living in deprived neighbor-
hoods have lower survival rates after an acute
myocardial infarction.18, 19
Individual factors associated with nonad-
herence may also be linked to an individual’s
neighborhood or community.  Social character-
istics of residential environments are associated
with the conduct of healthy behaviors.20
Evidence supports the concept that residential
neighborhoods play a role in determining
individual behaviors linked to health outcomes,
which primarily have been studied in diet and
exercise.21, 22 It may be hypothesized that
medication-taking behavior is also linked to
neighborhood or geographic characteristics.
Recent studies have documented that drug
prescribing and adherence vary based on
geography.  For example, adherence to drugs
used for the treatment of diabetes mellitus varies
by region in which the patient lives in the United
States.23 Other studies have documented
geographic variation in the prescribing of drugs
such as opiates and antiretroviral treatment.24, 25
A relatively new analytic technique, spatial
epidemiology, combines the disciplines of
geography, statistics, and epidemiology.26 Among
the tools used in these analyses are mapping
computer programs.  Programs known as
geographic information systems (GIS) are
capable of not only mapping any type of data that
can be linked to an address, or geocoded, but also
performing statistical analyses that examine
spatial relationships between variables.  Related
to drug therapy, GIS technology has been used to
study variations in prescribing controller asthma
drugs, based on clinical guidelines, for pediatric
patients with asthma.27 A GIS program was used
successfully to assess the impact of a large-scale
distribution program for nicotine replacement
therapy in New York City.28 In addition, GIS was
proven to be a useful tool to detect local patterns
of opiate drug prescribing and use.  Such was the
case in a study that tracked opiate prescribing
and use in New Mexico.29
There may be a link between medication-
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taking behavior and neighborhood or geographic
area characteristics.  A new approach to identi-
fying population or spatially associated, commu-
nity-based variables may be the use of GIS tech-
nology.  The first step in assessing the usefulness
of GIS is to test the feasibility of mapping drug
adherence in an effort to identify variations based
on geography.  Once the feasibility is established,
further work can begin to determine the neigh-
borhood or spatially related factors that are asso-
ciated with adherence variation.  Data that can be
used for these analyses would include census data,
population survey data such as the Behavioral
Risk Factor Surveillance System available from
the Centers for Disease Control and Prevention,
or locally obtained information including health
system infrastructure.
The purpose of this study was to determine the
feasibility of using GIS technology to document
geographic areas of high and low drug adherence
in patients who were discharged from a large
university-based hospital with continuing treat-
ment related to ACS.  To date, there are relatively
few studies using GIS technology to assess drug
adherence on a community or neighborhood
level.
Methods
The Acute Coronary Syndrome Patient Registry
This retrospective study used data obtained
from a registry of patients admitted to and
discharged from a large university-affiliated
medical center for the treatment of ACS.  The
registry uses data obtained from patients’ medical
records as well as a telephone follow-up survey of
the patients obtained 6–12 months after
discharge.  All patients aged 18 years or older
who were discharged between April 1999 and
December 2004 with the documented discharge
diagnosis of an ACS event—unstable angina or
acute myocardial infarction—were eligible for
inclusion in the registry.  Inclusion criteria were
documentation of unstable angina or myocardial
infarction using standard criteria such as
electrocardiogram changes, cardiac enzyme level
changes, and patient-reported symptoms.  Other
inclusion criteria were the ability to understand
English and communicate verbally by telephone.
Registry data included demographic and
clinical characteristics such as age, sex, education,
and comorbid conditions.  The address where the
patient lived at the time of the index ACS event
was also documented.  Drug data in the registry
included a complete list of drugs prescribed at
the time of discharge, obtained from the medical
record.  Another list of drugs obtained by patient
self-report during the follow-up survey was also
documented in the registry.  Four cardiac-specific
drug categories were derived from the lists and
included -blockers, ACE inhibitors, statins, and
aspirin.
Determination of continuation of the cardiac-
specific drugs was made by comparing the list of
drugs prescribed at discharge for the index ACS
event with the list of drugs reported by the
patient at the time of the telephone survey.30
Patients who discontinued any one of the four
drugs were classified as nonadherent.
Patients who were admitted multiple times
during the study time frame were counted once,
and their most recent address and adherence data
were used for this analysis.
Mapping Process
A GIS program was used to map patient
addresses and adherence data to geographic
coordinates on a base map.  The GIS integrates
hardware, software, and data to allow a user to
store, analyze, manipulate, and present geograph-
ically referenced information, and it allows
investigators to visualize and interpret data in
ways that reveal relationships, patterns, and
trends in the form of maps and reports.  The
program contains a structured database from
which maps can be generated, allowing the user
to view geographic features and relationships,
and it usually contains a statistical package for
processing geographic information.  The software
used for this study was ArcGIS, version 9.3.1
(Esri Data Systems; Environmental Systems
Research Institute, Inc., Redlands, CA).
A spreadsheet that included patient addresses
and adherence data was merged with census tract
data and a base map of Michigan to form a map
that contained analyzable attributes.  The merging
process included ensuring a complete match of
all addresses to known places on the census tract
map.  Mismatches were reconciled through
observation of closeness to known addresses on
the map layer.  Patient data associated with
addresses that could not be reconciled were
removed.
Analysis
A drug adherence value was determined for
each registry patient for the four classes of drugs
used in this study (-blockers, ACE inhibitors,
statins, and antiplatelet drugs).  Drugs documented
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as prescribed at discharge and self-reported as
taken at the follow-up survey were considered
persistently taken, and that drug class was coded
as adherent.  A value of 1 was then assigned to
that drug class.  A value of 0 was assigned if a
drug was prescribed at discharge but the patient
indicated at the time of the follow-up survey that
the drug was not taken.  The final value for
adherence for each patient was deter-mined by
summing the adherence score for each drug class
prescribed at discharge and dividing by the
number of drug classes prescribed.  Being
adherent to all classes of drugs prescribed at
discharge was considered a value of 1.0, whereas
being nonadherent to all classes of drugs
prescribed at discharge resulted in a value of 0.0.
During the geocoding phase, one or more
patients from the registry were assigned to a
census tract based on their home address listed in
the ACS registry.  The value for drug adherence
assigned to a specific census tract was the average
of the adherence scores of the registry patients
assigned to that census tract.  An assumption for
this study is that people in the registry are similar
to those who live in the census tract in which
they reside.  It is important to realize that census
tracts can vary substantially in demographics and
that the registry patient may not be similar
demographically to the mean age and sex of their
assigned census tract.  To standardize based on
age, the mean adherence value derived for
individual census tracts was divided by the
number of people living in the census tract aged
40 years or older.  Forty years of age was chosen
as this is the age at which increased monitoring
and assessment of cardiovascular risk factors
begins based on guidelines.31
Hot Spot Analysis was used to determine exis-
tence of any spatial patterns to drug adherence.
The Getis-Ord Gi* statistic was calculated for the
census tract adherence value, resulting in a Z
score and a p value.  The Z score indicates where
high and low values cluster spatially.  A statisti-
cally significant hot spot (individual or grouping
of census tracts) will have a high value that is
surrounded by other census tracts with high
values.  A statistically significant cold spot will
have a low value that is surrounded by other
tracts with low values.  In this study, hot spots
are areas of higher adherence, whereas cold spots
930
Figure 1. Map of southeast Michigan census tracts, including distribution of registry patients and
delineation of census tracts by high and low adherence (Hot Spot Analysis).
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are areas of lowest adherence.  Analyses were
conducted at the census tract level by using the
percentage of nonadherent patients within a
census tract as a representation of the overall
adherence rate of that tract.  For the analyses, we
used a spatial weights matrix file with polygon
contiguity in which neighbors were defined as
tracts sharing a common edge.  Census tracts
without represented neighbors (census tracts
without at least one ACS registry patient) and
tracts that did not share a common border were
removed because the spatial analyses we used
were dependent on tracts having neighbors.
Census tracts without a registry patient were also
excluded from analysis.
Once areas of high, neutral, and low adherence
or persistence were identified, the mean ± SD of
the standardized adherence value for tracts
grouped as high, neutral, or low adherence values
were determined.  Because of the process by
which hot and cold spots are identified, values
for adherence in represented census tracts are not
assumed to be independent of each other.  Therefore,
comparative testing was not undertaken, since
traditional statistical methods require the units of
analysis to be independent from each other.
Results
A total of 2877 people were listed in the ACS
registry between April 1999 and December 2004.
Of these, 1101 had traceable addresses.  Lack of a
traceable address was the main reason why 1776
registry patients were not analyzed in this study.
This may have been due to a mismatch between
registry patient and the hospital system used to
retrieve the addresses, or addresses given by the
patients that were recorded at the time of hospital-
ization were either incorrect or were documented
incorrectly.  We were unable to confirm the
number of cases associated with each of these
common reasons for lack of traceable addresses.
Of the 1101 patients with traceable addresses,
1081 had complete drug data at discharge and
from the follow-up survey.  Reasons for lack of
drug data were not ascertained.  The 1081 patients
were distributed over 300 census tracts in south-
eastern Michigan.  Patients’ mean ± SD age was
63.4 ± 13.3 years, and 712 (65.9%) were male.
A comparison was performed between patients
in the geocoded group (1081 patients) and those
in the nongeocoded group (1776 patients).  The
adherence rate for patients in the group with
addresses and adherence data was significantly
higher compared with those who had adherence
rates available but no geocodable address (0.75 ±
0.25 vs 0.69 ± 0.27, p<0.001).  In addition,
patients in the geocoded group were younger by
1 year compared with those in the nongeocoded
group (mean ± SD age 63.3 ± 13.6 vs 64.3 ± 13.9
yrs, p=0.04).  Finally, the sex of the patients was
not significantly different between the geocoded
and nongeocoded groups (p=0.11).
Figure 1 is a map of the area included in this
analysis along with location of registry patients
within the census tracts within these counties.  It
should be noted that the area is primarily located
in Washtenaw, Jackson, Livingston, Monroe,
Oakland, Lenawee, and Wayne counties in
southeastern Michigan.  Geographically, the
University of Michigan Hospital, the source of
hospital care for the index ACS event, is centrally
situated in Washtenaw county, which is bordered
by the other six counties.
Hot Spot Analysis was able to delineate unique
geographic areas of high, neutral, and low
adherence in the southeast Michigan area (Figure
1).  High-adherence census tracts were primarily
located in and around the city of Ann Arbor, the
location of the university hospital and clinics.
The areas with low adherence were located to the
west, southwest, and southeast of the city of Ann
Arbor, roughly incorporating the Jackson county-
city area, city of Adrian, and city of Monroe.  All
other census tracts were considered neutral in
adherence rates.
The mean ± SD adjusted adherence rates for
the three categories of census tracts were as
follows:  high adherence 0.00063 ± 0.0019,
neutral adherence 0.00041 ± 0.0023, and low
adherence 0.00036 ± 0.00019.
Discussion
The results of this feasibility study show that
there is a spatial effect associated with adherence
to drug therapy in patients who had recently
been discharged after an ACS event.  It appears
that GIS technology may be a useful technique to
identify geographic areas of varying rates of
adherence.  This is important as a first step in
developing population-based assessment of drug
adherence by using GIS technology.  One impor-
tant issue yet to be resolved is the represen-
tativeness of the people mapped in a geographic
unit to the rest of the people who live there.
Further research is necessary to document that
these representative individuals are similar to the
at-risk population of that area.  Some census
tracts included only one or two registry patients.
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The assumption was that these individuals
represent all people aged 40 years or older in that
census tract.  Therefore, a limitation of this study
is the representativeness of the registry patients
to the at-risk population of their assigned census
tract.  It is also important to note that this study
was limited geographically, assessing people
living in the greater Ann Arbor area of Michigan
and extending to areas of southeastern Michigan.
Further research would be necessary to test the
technology in much larger geographic areas.  It
does demonstrate that, at the local level, assess-
ments of geographic variation in adherence are
possible.
Health is now understood to be influenced on
multiple levels, including the community and
societal influences.32, 33 In addition to further
work to validate GIS technology to assess adher-
ence at a population level, research must also be
conducted using mixed methods to identify local
beliefs and attitudes toward drug therapy, along
with identifying common local barriers to
accessing prescribed drugs.  This would provide
local public health practitioners and policymakers
the opportunity to develop tailored interventions
that are meaningful to a local population.
Several limitations in the study design and data
require discussion.  The patient registry included
only patients treated for ACS at a single, large,
university-based hospital in southeastern Michigan.
Patients treated at other local hospitals were not
included in this study.  Local effects related to
hospital and health system characteristics, such
as discharge counseling and follow-up communi-
cation with community providers, as well as
provision of local community health programs
targeting patients with ACS, were not assessed.
Future research could identify not only patient
and population characteristics, but also the
differences in local health systems procedures
that may be associated with local population
health beliefs, attitudes, and practices.
Another limitation of the study was the fact
that many patients in the ACS registry did not
have addresses that we could geocode and map.
Unfortunately, this is an inherent problem when
using a registry or database that was built for
other purposes.  We were not able to determine
why addresses were not able to be mapped, but
only able to state that they were missing.  Future
research in this area should include prospective
data collection efforts that would preemptively
ensure the accuracy and completeness of addresses
obtained from subjects in the study sample.
The method of determining drug adherence
should also be discussed as a limitation of the
study.  Most measures of adherence or persistence
with prescription drugs are at best surrogates for
actual taking of the drug.  We used a method that
included identification of drugs prescribed at
discharge coupled with self-report of the drugs
taken at the time of a relatively short-term (< 12
mo) follow-up.  Other methods for determining
adherence would include pharmacy claims data,
capture of drug container openings by using an
electronic surveillance method, or use of a
standardized, validated self-report instrument.
Future research may use mixed methods to assess
adherence as an attempt to improve the measure-
ment procedure.
Another limitation related to our method of
determining adherence is that reasons for
discontinuation of a drug were not obtained for
all patients.  For example, drugs discontinued by
a physician’s order due contraindications or
adverse effects would have been classified as the
nonadherent drug category.  Future research
should include assessment of patient-reported
reasons for nonadherence.
Despite the limitations, this study demonstrated
the potential of using GIS technology to identify
geographic areas of relatively lower drug adherence.
Mapping drug adherence by using a GIS program
may be a useful tool that public health practi-
tioners, local health care providers, and researchers
can use to identify local geographic areas where
adherence is not optimal.  Through further quali-
tative and quantitative studies, interventions
developed by using locally relevant information
on barriers to appropriate use of prescribed drugs
may have a higher success rate than using gener-
alized interventions to improve drug adherence
in a community.  Targeting communities with
poor adherence may prove cost-effective compared
with interventions for individual patients.  Some
examples of community interventions would be
educating patients with health announcements
over local radio or in newspapers, as well as
educating health professionals on the importance
of maintaining good communication with patients
in their area.  These strategies would target not
only patients, but also the social network that
includes local friends, acquaintances, and family
members whose influence has been shown to
positively affect compliance with medical
recommendations.34
Conclusion
This study has demonstrated the feasibility of
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using GIS technology to study drug adherence.
Spatial mapping can be used to detect areas of
low drug adherence.  Using this information,
health professionals may identify geographic
areas that, once an understanding of the local
contextual effects associated with poor adherence
are identified, could help develop target interven-
tions to specific areas rather than using general
population interventions or one-on-one indivi-
dual approaches.
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